Search Results for "clozapine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for clozapine. Results 1 to 3 of 3 total matches.
See also: Clozaril, Fazaclo

In Brief: REMS Removal for Clozapine

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2025  (Issue 5103)
In Brief: REMS Removal for Clozapine ...
The FDA has announced that prescribers, pharmacies, and patients are no longer required to participate in a Risk Evaluation and Mitigation Strategy (REMS) program for the second-generation antipsychotic drug clozapine (Clozaril, and others).
Med Lett Drugs Ther. 2025 Mar 27;67(5103):1   doi:10.58347/tml.2025.5103a |  Show IntroductionHide Introduction

Lumateperone (Caplyta) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
in efficacy over first-generation drugs, except for clozapine (Clozaril, and others) for treatment-resistant ...
The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):113-6 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
other antipsychotics, it may increase the risk of mortality in elderly patients with psychosis. Clozapine (Clozaril ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction